POLARIS-2: Study of Olverembatinib (HQP1351) in Patients With CP-CML

Condition: Chronic Myeloid Leukemia

Sponsor: Ascentage Pharma Group Inc.

Full Title
Protocol HQP1351CG301: A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia

Study Treatment
Third-generation BCR-ABL1 tyrosine kinase inhibitor Olverembatinib vs bosutinib

Eligibility/Info
Eligible patients must have chronic phase chronic myeloid leukemia without a history of accelerated or blastic phase.
Part A: Treatment with at least two prior TKIs and confirmed absence of T315I and V229L mutations
Part B: Confirmed presence of T315I mutation, prior treatment with at least 1 TKI, and lack of other effective/tolerable therapies

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage